Lantern Pharma (NASDAQ: LTRN), an AI-native precision oncology company, announced that the European Medicines Agency (EMA) has cleared an investigator-initiated Phase 1b/2 clinical trial evaluating lead drug candidate LP-184 (zirdafulven) in patients with advanced or metastatic bladder cancer. The biomarker-guided study will be conducted at Rigshospitalet in Copenhagen, Denmark, and will enroll up to 39 patients. Participants will be prospectively selected based on PTGR1 overexpression and DNA-damage-repair deficiency, marking a significant step in personalized cancer treatment.
According to Lantern, the trial will evaluate LP-184 in patients who have progressed on or are ineligible for current standard-of-care therapies. This addresses a critical unmet need, as bladder cancer patients often face limited options after first-line treatments fail. The study also advances Lantern's AI-driven precision oncology strategy through its proprietary RADR platform, which uses artificial intelligence and machine learning to identify biomarkers and optimize drug development.
“EMA clearance for our LP-184 bladder cancer trial is a key milestone, demonstrating the potential of our RADR platform to guide clinical development in a biomarker-defined population,” said a Lantern spokesperson. The company believes this approach could improve response rates and reduce side effects compared to traditional chemotherapy.
The implications for the industry are substantial. Lantern’s use of the RADR platform to select patients based on PTGR1 overexpression and DNA repair deficiency exemplifies a broader shift toward precision oncology, where treatments are tailored to genetic profiles. If successful, LP-184 could become a new option for bladder cancer patients with specific biomarkers, potentially expanding the market for targeted therapies. For leaders in business and technology, this underscores the growing role of AI in drug discovery and clinical trial design, which could reduce costs and accelerate time-to-market for novel treatments.
Lantern’s clinical pipeline also includes LP-284, a TC-NER targeting compound in hematologic and solid tumors, and LP-300, which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary. Additionally, withZeta.ai, Lantern’s multi-agentic AI co-scientist platform, is now commercially available as a subscription-based research platform, representing a new revenue stream for the company.
Lantern operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas. The company’s focus on AI-native drug development positions it at the forefront of a transformative trend in biotechnology, where data-driven insights are increasingly critical to success. For investors and industry observers, this trial clearance signals progress in Lantern’s pipeline and validates its AI-centric approach.
More information about the trial and Lantern’s pipeline can be found in the full press release at https://ibn.fm/6ku4F. Updates on Lantern Pharma are available in the company’s newsroom at https://ibn.fm/LTRN.
